Invention Grant
- Patent Title: Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
-
Application No.: US15511405Application Date: 2015-09-16
-
Publication No.: US10233230B2Publication Date: 2019-03-19
- Inventor: Sang Youn Hwang , Jin Young Kim , Seung Su Kim , In Young Choi , Sung Youb Jung , Se Chang Kwon
- Applicant: HANMI PHARM. CO., LTD.
- Applicant Address: KR Hwaseong-Si, Gyeonggi-Do
- Assignee: Hanmi Pharm. Co., Ltd.
- Current Assignee: Hanmi Pharm. Co., Ltd.
- Current Assignee Address: KR Hwaseong-Si, Gyeonggi-Do
- Agency: Baker & Hostetler LLP
- Priority: KR10-2014-0122862 20140916
- International Application: PCT/KR2015/009753 WO 20150916
- International Announcement: WO2016/043533 WO 20160324
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K16/00 ; A61K38/26 ; A61K49/00 ; A61K47/60 ; A61K47/68 ; A61K47/48

Abstract:
The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.
Public/Granted literature
Information query
IPC分类: